Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adverse events reported during weekly isoniazid-rifapentine (3HP) tuberculosis preventive treatment among people living with HIV in Uganda.
Kadota JL, Musinguzi A, Aschmann HE, Akello L, Welishe F, Nakimuli J, Berger CA, Kiwanuka N, Phillips PP, Katamba A, Dowdy DW, Cattamanchi A, Semitala FC. Kadota JL, et al. Among authors: berger ca. medRxiv [Preprint]. 2024 Aug 9:2024.08.08.24311632. doi: 10.1101/2024.08.08.24311632. medRxiv. 2024. PMID: 39148841 Free PMC article. Preprint.
Management and Outcomes of Critically-III Patients with COVID-19 Pneumonia at a Safety-net Hospital in San Francisco, a Region with Early Public Health Interventions: A Case Series.
Vanderburg S, Alipanah N, Crowder R, Yoon C, Wang R, Thakur N, Slown K, Shete PB, Rofael M, Metcalfe JZ, Merrifield C, Marquez C, Malcolm K, Lipnick M, Jain V, Gomez A, Burns G, Brown LB, Berger C, Auyeung V, Cattamanchi A, Hendrickson CM. Vanderburg S, et al. medRxiv [Preprint]. 2020 May 29:2020.05.27.20114090. doi: 10.1101/2020.05.27.20114090. medRxiv. 2020. PMID: 32511538 Free PMC article. Preprint.
Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda.
Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba A, Dowdy D, Semitala FC, Cattamanchi A. Kadota JL, et al. Among authors: berger ca. Implement Sci. 2020 Aug 12;15(1):65. doi: 10.1186/s13012-020-01025-8. Implement Sci. 2020. PMID: 32787925 Free PMC article.
Variation in tuberculosis treatment outcomes and treatment supervision practices in Uganda.
Berger CA, Kityamuwesi A, Crowder R, Lamunu M, Kunihira Tinka L, Ggita J, Sanyu Nakate A, Namale C, Oyuku D, Chen K, Turyahabwe S, Cattamanchi A, Katamba A. Berger CA, et al. J Clin Tuberc Other Mycobact Dis. 2020 Sep 12;21:100184. doi: 10.1016/j.jctube.2020.100184. eCollection 2020 Dec. J Clin Tuberc Other Mycobact Dis. 2020. PMID: 33204851 Free PMC article.
Study protocol and implementation details for a pragmatic, stepped-wedge cluster randomised trial of a digital adherence technology to facilitate tuberculosis treatment completion.
Crowder R, Kityamuwesi A, Kiwanuka N, Lamunu M, Namale C, Tinka LK, Nakate AS, Ggita J, Turimumahoro P, Babirye D, Oyuku D, Berger CA, Tucker A, Patel D, Sammann A, Dowdy D, Stavia T, Cattamanchi A, Katamba A. Crowder R, et al. Among authors: berger ca. BMJ Open. 2020 Nov 27;10(11):e039895. doi: 10.1136/bmjopen-2020-039895. BMJ Open. 2020. PMID: 33247012 Free PMC article.
Digital adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial in Uganda.
Cattamanchi A, Crowder R, Kityamuwesi A, Kiwanuka N, Lamunu M, Namale C, Tinka LK, Nakate AS, Ggita J, Turimumahoro P, Babirye D, Oyuku D, Berger C, Tucker A, Patel D, Sammann A, Turyahabwe S, Dowdy D, Katamba A. Cattamanchi A, et al. PLoS Med. 2021 May 6;18(5):e1003628. doi: 10.1371/journal.pmed.1003628. eCollection 2021 May. PLoS Med. 2021. PMID: 33956802 Free PMC article. Clinical Trial.
Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives.
Semitala FC, Musinguzi A, Ssemata J, Welishe F, Nabunje J, Kadota JL, Berger CA, Katamba A, Kiwanuka N, Kamya MR, Dowdy D, Cattamanchi A, Katahoire AR. Semitala FC, et al. Among authors: berger ca. Implement Sci Commun. 2021 Jun 30;2(1):71. doi: 10.1186/s43058-021-00173-2. Implement Sci Commun. 2021. PMID: 34193311 Free PMC article.
Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Semitala FC, et al. Among authors: berger ca. PLoS Med. 2021 Dec 16;18(12):e1003875. doi: 10.1371/journal.pmed.1003875. eCollection 2021 Dec. PLoS Med. 2021. PMID: 34914696 Free PMC article. Clinical Trial.
57 results